<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50294">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932229</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-9547-JB-CTIL</org_study_id>
    <nct_id>NCT01932229</nct_id>
  </id_info>
  <brief_title>An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib</brief_title>
  <official_title>An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced lung cancer (non-small cell lung cancer) with a mutation in the EGFR (epidermal
      growth factor receptor) gene, which have disease progression after treatment with an EGFR
      inhibitor (erlotinib or gefitinib), and have progression of disease also after treatment
      with chemotherapy will be recruited. The trial has only one arm, of afatinib daily
      treatment. Blood and exhaled breath samples will be collected for investigations aiming to
      identify factors that predict response to afatinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Afatinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib treatment</intervention_name>
    <arm_group_label>Afatinib treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced NSCLC

          -  EGFR mutation or six months or longer benefit from EGFR TKIs

          -  Disease progression on chemotherapy, or inability to receive chemotherapy for medical
             reasons.

          -  Disease progression on EGFR TKI, or the presence of an EGFR mutation that does
             predicts for poor response to first generation EGFR TKIs.

        Exclusion Criteria:

          -  Inability to take oral drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jair Bar, MD-PhD</last_name>
    <phone>+972-3-530-7096</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina Vornstein, B.A.</last_name>
    <email>Diana.Vorenshtein@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gat</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Vornstein</last_name>
      <email>Diana.Vorenshtein@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Jair Bar, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced NSCLC</keyword>
  <keyword>EGFR mutation</keyword>
  <keyword>TKIs</keyword>
  <keyword>Tyrosine Kinase Inhibitors</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
